FDA
-
-
-
-
-
-
-
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
-
-
-
-
-
-
-
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
-
-
-
-
-
-
-
Pre-Open Movers 08/26: (FLDM) (DKS) (CRM) Higher; (PSTG) (LRN) (JWN) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Stock Movers 05/11: (MYOK) (AMC) (AVYA) Higher; (VUZI) (UA) (PENN) Lower (more...)
-
-
-
-
-
335,219 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


